Bella Mehta bella_mehta
2 years 4 months ago
Treat to target in #lupus - difficult for many reasons.
Also may be too much of a restrictive strategy.
@Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n
Bella Mehta bella_mehta
2 years 4 months ago
Many drugs in the horizon for #lupus @Lupusreference lecture #EULAR2024
Loved the timeline of all major drug -phase 2 and 3 drugs.
Need for new strategies in Lupus – outcomes and survival is plateauing!
@RheumNow https://t.co/Ue239woQJr
Bella Mehta bella_mehta
2 years 4 months ago
Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session.
Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5
Bella Mehta bella_mehta
2 years 4 months ago
Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon.
Looking forward to playing with this. #LLMs #ChatGPT
More to come. @RheumNow https://t.co/mGXG6A85Hx
Bella Mehta bella_mehta
2 years 4 months ago
Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024
We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR
TheDaoIndex KDAO2011
2 years 4 months ago
@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn
Bella Mehta bella_mehta
2 years 4 months ago
Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024
Bella Mehta bella_mehta
2 years 4 months ago
Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls.
Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids)
@RheumNow https://t.co/Fz1dZUVomF
TheDaoIndex KDAO2011
2 years 4 months ago
Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow
Mrinalini Dey DrMiniDey
2 years 4 months ago
💊 Difficult-to-treat #SpA & #PsA
🤔 What are the challenges in assessing persistently active disease?
🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease
🌎 Great to see #comorbidities highlighted
@RheumNow
#EULAR2024 https://t.co/x4jUTOC3li
TheDaoIndex KDAO2011
2 years 4 months ago
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24
Dr. Antoni Chan synovialjoints
2 years 4 months ago
Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6
Peter Nash drpnash
2 years 4 months ago
CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e
Aurelie Najm AurelieRheumo
2 years 4 months ago
« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett
Are we finally looking at the « visionary scenario »?
@RheumNow #EULAR2024 https://t.co/tzfDormeIl
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 4 months ago
@Janetbirdope @RheumNow #EULAR2024 JAK-i Debate
@drdavidliew (NOT in support of regulation)
- is the signal real? Query about replicability & data came from N. America. Not reflected on real-world data of enriched cohorts
- is the warning justified?
- are there unintended consequences?
@RheumNow https://t.co/TXUf90fqwN
